Disc Medicine Reports $59.5 Million Net Loss in Q2 2026, Increased Operating Expenses

Disc Medicine, Inc. reported a net loss of $59.5 million for the second quarter of 2026, compared to a net loss of $55.2 million for the same period in 2025. For the first half of 2026, the company’s net loss increased to $123.0 million from $89.3 million in the prior year. The increase in losses was attributed to higher operating expenses, which rose to $65.1 million in Q2 2026 from $61.4 million in Q2 2025, and to $134.6 million for the first half of 2026, up from $101.4 million in the same period last year. The company has not generated any revenue since its inception and continues to anticipate significant operating losses as it advances its clinical development programs.

Research and development expenses for the second quarter of 2026 were $46.9 million, slightly higher than the $46.3 million reported in the same quarter of 2025. The increase was primarily driven by costs associated with the advancement of clinical trials for its product candidates, particularly selcodebart (DISC-0974) and DISC-3405. Selling, general, and administrative expenses also rose to $18.1 million in Q2 2026 from $15.1 million in Q2 2025, reflecting increased personnel costs and stock-based compensation. The company’s accumulated deficit reached $633.2 million as of June 30, 2026.

In terms of liquidity, Disc Medicine reported cash, cash equivalents, and marketable securities totaling $717.7 million as of June 30, 2026, a decrease from $791.2 million at the end of 2025. The company believes this amount will be sufficient to fund its operations and capital expenditures into 2029. However, it also noted the potential need for additional capital to support ongoing clinical trials and commercialization efforts, which could come from equity or debt financing, collaborations, or licensing arrangements.

Operationally, Disc Medicine is focused on its pipeline of product candidates targeting hematologic diseases. The company is advancing its lead candidate, bitopertin, through a Phase 3 clinical trial for the treatment of erythropoietic porphyrias. The FDA has accepted its New Drug Application for review, although a complete response letter was issued in February 2026, indicating that further data from ongoing trials may be necessary for approval. The company is also progressing with clinical trials for selcodebart and DISC-3405, with initial data expected in the coming quarters.

Looking ahead, Disc Medicine remains committed to its research and development strategy, with plans to continue advancing its clinical programs. The company is preparing for potential commercialization of its product candidates, contingent upon successful clinical outcomes and regulatory approvals. However, it acknowledges the inherent risks and uncertainties in the biotechnology sector, including the need for substantial funding and the challenges of bringing new therapies to market.